Orphan Drug Advantage Leverage FDA Orphan Drug Designation and strong IP for ENB-001 to position partnerships and co-development deals that emphasize market exclusivity and accelerated regulatory pathways in oncology.

Immunotherapy Synergy Target collaboration opportunities with immuno-oncology players to combine ENB-001 with PD-1/PD-L1 inhibitors or other immunotherapies, highlighting potential to restore T-cell tumor infiltration and extend patient survival.

Companion Diagnostics Market ENB-001 alongside the planned companion diagnostic to identify ETBR pathway over-expressers, enabling indication expansion and precision medicine partnerships across multiple solid tumor types.

Strategic Partnerships Capitalize on past and recent partnerships with Merck and HITLAB to prospect additional pharma/biotech co-development or translational research deals, particularly in early-phase trials and biomarker-driven programs.

Financial Readiness With a lean team and modest revenue base, pursue sponsorships, milestone-driven collaborations, and grant-funded programs to secure non-dilutive funding while advancing ENB-001 milestones within an 18-month near-term POC window.